ARTICLE | Company News

iPharma gets rights to Boehringer's FAK inhibitor

November 10, 2017 9:24 PM UTC

Boehringer Ingelheim GmbH (Ingelheim, Germany) granted iPharma Ltd. exclusive, worldwide rights to develop and commercialize BI 853520, a focal adhesion kinase inhibitor. iPharma is a JV formed in August 2016 by BioLineRx Ltd. (Tel Aviv:BLRX; NASDAQ:BLRX) and I-Bridge Capital (see BioCentury, Sept. 5, 2016).

Boehringer will receive an undisclosed upfront payment and is eligible for milestones and royalties...